GCP
VNRX icon

GSA Capital Partners’s VolitionRx Ltd VNRX Stock Holding History

GSA Capital Partners’s Portfolio VNRX Stock Details VNRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,386
Closed -$105K – 1616
2021
Q1 		$105K Sell
1,386
-4,411
-76% -$378K 0.02% 998
2020
Q4 		$451K Buy
5,797
+134
+2% +$9.22K 0.07% 482
2020
Q3 		$364K Buy
+5,663
New +$385K 0.06% 608

Other funds holding VNRX

LIM
Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSA Capital Partners's VNRX Position: Q2 2021 in Review

GSA Capital Partners sold out of VolitionRx Ltd (VNRX) in Q2 2021, closing a stake of 1,386 shares — an estimated $105K sold.

GSA Capital Partners first reported a position in VNRX in Q3 2020 and held it in 3 quarters. The position peaked at $451K in Q4 2020. 46 funds tracked by Wall St. Rank hold VNRX as of Q2 2021.

  • GSA Capital Partners reported no remaining VolitionRx Ltd position as of Q2 2021 after selling out during the quarter.
  • GSA Capital Partners sold 1,386 VolitionRx Ltd shares in Q2 2021, an estimated $105K.
  • GSA Capital Partners first reported a position in VolitionRx Ltd in Q3 2020 and held it in 3 quarters.
  • GSA Capital Partners's VolitionRx Ltd position peaked at $451K in Q4 2020.
  • 46 funds tracked by Wall St. Rank held VolitionRx Ltd as of Q2 2021.

Based on GSA Capital Partners's 13F filing for Q2 2021, filed 5 Aug 2021.